We found a shift in the significance of the receptors for tumor recurrence; higher rates of AR expression are unfavorable for prostate tumor in younger patients, however it loses its significance in the oldest group, in contrast to ESR1, where higher expression is generally unfavorable. This evidence concerns the gene AR and neoplasm.